| Company Name | Bristol-Myers Squibb (Taiwan) Ltd. |
|---|---|
| Protocol Number | CA204-219 |
| Title of Study | Empliciti® (elotuzumab) Post-marketing Surveillance Study for Patients with Multiple Myeloma in Taiwan |
| Primary Objective | The primary objective of this study is to collect the safety data for the period of 25 weeks or to 30 days after discontinuation of Empliciti (elotuzumab) treatment in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) in Taiwan. Safety data in this study include adverse events (AEs), serious adverse events (SAEs), and AEs of special interest (AESI) occurring in the study duration. |
| Number of Sites | 1 |
| Period of Study | From：2023/01 to：2025/12 |
| Number of Patients | 27人 |
| IRB Approval Date | NTUH:2023/09/05 |
| Publication Plan / Date | 2026/01/01 |
